Our patented biologics platform technology AbiProt™ identifies new therapeutic antibodies that not only bind to a target protein with high specificity and affinity — in many cases they can also be programmed to have a particular pharmacological action. We call these antibodies FTABS™. We believe the technology will enable the development of more effective medicines against target proteins that cannot be addressed with traditional antibody technology. Instead, our technology focuses on GPCRs and ion channels as well as previously undruggable targets.

      A new beginning for effective targets that failed due to severe toxicity.